Cancer Research Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arlt, M.
Right arrow Articles by Krüger, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arlt, M.
Right arrow Articles by Krüger, A.
[Cancer Research 62, 5543-5550, October 1, 2002]
© 2002 American Association for Cancer Research


Tumor Biology

Increase in Gelatinase-specificity of Matrix Metalloproteinase Inhibitors Correlates with Antimetastatic Efficacy in a T-Cell Lymphoma Model1

Matthias Arlt, Charlotte Kopitz, Caroline Pennington, Katrina L. M. Watson, Hans-Willi Krell, Wolfram Bode, Bernd Gansbacher, Rama Khokha, Dylan R. Edwards and Achim Krüger2

Institut für Experimentelle Onkologie und Therapieforschung, Technische Universität München, D-81675 München, Germany (M. A., C. K., B. G., A. K.); University of East Anglia, School of Biological Sciences, Norwich, Norfolk NR4 7TJ, United Kingdom (C. P., D. R. E.); University of Toronto, Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada (K. L. M. W., R. K.); Max-Planck-Institut für Biochemie, D-82152 Martinsried, Germany (W. B.); and Roche Diagnostics GmbH, D-82377 Penzberg, Germany (H. W. K.)

The recognition that matrix metalloproteinases (MMPs) facilitate tumor cell invasion and metastasis has led to the development of synthetic MMP inhibitors (MMPIs) as cancer therapeutic agents. Because several Phase III trials failed recently to show efficacy of broad-spectrum MMPIs in advanced cancer, the feasibility of MMPs as therapeutic targets has been challenged. However, it has not yet been determined whether MMPIs that have increased specificity may have greater benefit. We show that MMP-9 expression closely correlates with the progression of liver metastasis in a T-cell lymphoma model. MMPIs with greater selectivity/specificity for MMP-9 in vitro showed greater efficacy against liver metastasis in vivo. These data demonstrate a link between increased specificity of MMPIs and enhanced anticancer activity.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.